Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Perspective Therapeutics, Inc.AMEX: CATX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $26.19M (cash outflow) rose 44.1% year over year, ahead of the +30.5% change in trailing-twelve-month net income. Sequentially, it fell 30.1% from the prior quarter. Over 3 fiscal years it compounded at +91.6% a year.

Context

  • Net income amounted to 11665.3% of revenue in FY2025, up 6212.8 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$72.57M (-29.6%) for the fiscal year ending Dec 2026, a slowdown from the +30.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.19M-30.1% QoQ
Last fiscal yearDec 2025
-$103.12M+30.1% YoY
LTMMar 2026
-$111.13M+30.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.1%+41.1%-3.0 pp
1 year+30.1%-29.6%-59.7 pp
3-year CAGR+91.6%-12.6%-104.2 pp
5-year CAGR-17.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(103.12M) USD
Year-over-year change
-30.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 net income of $111.13M is the 2nd largest of the 5 companies compared; the peer median is $17.54M.
  • Its year-over-year change of +30.5% is the 2nd highest of 5, against a peer median of +2.9%.
  • Net income amounts to 17982.7% of revenue for CATX, versus a peer median of 30.1%.
CATX Competitors Peer median
Net Income for CATX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$173.05M +5.4%+13.8%25.7%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$111.13M +30.5%+91.6%17982.7%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$27.31M +0.4%-6.0%60.9%
SRTSSensus Healthcare, Inc.LTM Mar 2026$7.77M -531.6%—34.5%
DCTHDelcath Systems, Inc.LTM Mar 2026$561K +103.9%—0.6%
Peer median (excluding CATX) $17.54M+2.9%+3.9%30.1%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(7.27M)(14.67M)(46.51M)(79.28M)(103.12M)
Depreciation & Amortization248K344K946K2.31M3.25M
Deferred Income Tax0(1.68M)(2.65M)(2.1M)(793K)
Stock-Based Compensation1.09M1.34M3.74M5.39M8.97M
Change in Working Capital(1.85M)338K2.3M31.81M1.68M
Accounts Receivables405K490K(426K)1.05M(32K)
Inventory(2.67M)(152K)359K11K0
Accounts Payables236K01.58M1.89M147K
Other Working Capital182K(28K)779K29.74M1.57M
Other Non-Cash Items77K472K5.27M55.39M7.53M
Operating Cash Flow(7.71M)(12.17M)(36.91M)(18.29M)(82.48M)
Capital Expenditures(266K)(302K)(1.07M)(54.41M)(12.75M)
Acquisitions (Net)002.7M00
Purchases of Investments000(243.51M)(119.84M)
Sales of Investments0022.76M0173.95M
Other Investing Activities(18K)(57.38M)(18K)78.99M(135K)
Investing Cash Flow(284K)(57.68M)24.37M(218.93M)41.23M
Debt Repayment——(68K)(48K)(52K)
Common Stock Issued56K0364K275.81M10.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities056K489K289.39M0
Financing Cash Flow56K56K785K289.39M10.31M
Effect of Forex Changes061.86M000
Net Change in Cash(7.94M)182K(46.65M)52.16M(30.95M)
Free Cash Flow(7.98M)(12.47M)(37.99M)(72.71M)(95.23M)

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.